Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of KACM001 autologous lymphocyte injection plus PD-1 antibody and XELOX as first-line treatment for unresectable locally advanced or metastatic gastric cancer
CTR20260723Phase 2Active
- Sponsor
- Kangairuihao Biotechnology
- Start
- Feb 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of KACM001 autologous lymphocyte injection in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Kangairuihao Biotechnology. Started Feb 2026; status: active.
02
Drugs
KACM001 autologous lymphocyte injection
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20260723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260723.